A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Clinical trial NCT02903381 · COMPLETED
Trial details
- NCT number
- NCT02903381
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-20
- Primary completion
- 2018-06-28
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.